In a filing, MetLife Inc. revealed its EVP & Chief Risk Officer DEBEL MARLENE unloaded Company’s shares for reported $0.59 million on Aug 09. In the deal valued at $63.18 per share,9,391 shares were sold. As a result of this transaction, DEBEL MARLENE now holds 77,638 shares worth roughly $ 4.85 million.
Then, PAPPAS BILL sold 2,857 shares, generating $202,733 in total proceeds. Upon selling the shares at $70.96, the EVP, Global Tech. & Ops. now owns 48,915 shares.
Before that, PAPPAS BILL sold 11,345 shares. MetLife Inc. shares valued at $816,386 were divested by the EVP, Global Tech. & Ops. at a price of $71.96 per share. As a result of the transaction, PAPPAS BILL now holds 46,231 shares, worth roughly $2.89 million.
Goldman downgraded its MetLife Inc. [MET] rating to a Neutral from a a Buy in a research note published on Monday, January 09, 2023; the price target was decreased to $78 from $80. PT values the company’s stock at a premium of 19.83 to its Monday closing price.
Price Performance Review of MET
On Monday, MetLife Inc. [NYSE:MET] saw its stock jump 0.19% to $62.53. On the same session, the stock had its day’s lowest price of $62.325, but rose to a high of $62.99. Over the last five days, the stock has gained 0.94%. MetLife Inc. shares have fallen nearly -13.60% since the year began. Nevertheless, the stocks have fallen -7.05% over the past one year. While a 52-week high of $77.36 was reached on 01/06/23, a 52-week low of $48.95 was recorded on 05/16/23. SMA at 50 days reached $59.96, while 200 days put it at $63.70. A total of 2.13 million shares were traded, compared to the trading of 2.11 million shares in the previous session.
Levels Of Support And Resistance For MET Stock
The 24-hour chart illustrates a support level at 62.24, which if violated will result in even more drops to 61.95. On the upside, there is a resistance level at 62.90. A further resistance level may holdings at 63.28. The Relative Strength Index (RSI) on the 14-day chart is 55.98, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 49.32%. Stochastics %K at 43.67% indicates the stock is a holding.
How much short interest is there in MetLife Inc.?
A steep rise in short interest was recorded in MetLife Inc. stocks on Aug 14, 2023, dropping by -2.41 million shares to a total of 7.81 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 10.22 million shares. There was a decline of -30.86%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.24% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.11.
MetLife Inc. [MET] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 56,444,080 shares, or roughly 7.37% of the outstanding MET shares. In other words, the investor’s shares have fallen by -864,049 from its previous 13-F filing of 57308129.0. Additionally, Dodge & Cox increased 0.16% of its stake after which the total value it holdings stand at $3,410,058,426, while T. Rowe Price Associates, Inc. added 32.47% of its stake to hold $2.22 billion in the firm. Over the last quarter, BlackRock Fund Advisors sold -901,464 shares of MetLife Inc., while Wellington Management Co. LLP sold -7,397,338 shares. At present, SSgA Funds Management, Inc. is holding 28,668,631 shares valued at $1.81 billion. Geode Capital Management LLC owned 11,725,316 shares of the company at the time of its most recent 13F filing, worth $738.34 million.
According to FactSet, MetLife Inc.’s share price will average $76.60 in the next year, based on opinions of analysts polled by the firm. This is up nearly 27.38 percent from its previous closing price of $62.41. Analysts expect MetLife Inc. stock to reach the higher price of $85.00, while the lowest price estimate is $58.00. However, 18 analysts have rated MET stock as an Overweight in their predictions for 2023.